Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis

Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis

BackgroundThere is little evidence of the effectiveness of switching from the endothelin receptor antagonists (ERAs) bosentan and ambrisentan to a novel ERA, macitentan, in patients with pulmonary arterial hypertension (PAH). Therefore, a systematic review and meta-analysis was performed to evaluate...

Full description

Bibliographic Details
Main Authors: Jie Li, Zu-Yuan Yang, Shang Wang, Ping Yuan, Qin-Hua Zhao, Su-Gang Gong, Hong-Ling Qiu, Ci-Jun Luo, Hui-Ting Li, Rui Zhang, Wen-Hui Wu, Jin-Ming Liu, Lan Wang, Shan-Shan Liu, Rong Jiang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
endothelial receptor antagonists
pulmonary arterial hypertension
macitentan
6-min walk distance
bosentan
ambrisentan
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.977110/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.977110/full

Similar Items